"2021 Drug Digital Intelligence Development Conference" was held in Hefei, Anhui Province

In order to meet the needs of the digital and intelligent development of the pharmaceutical industry in the new era, explore new ideas and new methods of big data technology in the pharmaceutical industry, build a sharing intelligent regulatory exchange platform, defend the network and data security position, and promote the high-quality development of the pharmaceutical industry, September 27 to 28, The "2021 Drug Digital Intelligence Development Conference" hosted by the Information Center of the State Drug Administration (China Food and Drug Regulatory Data Center) was held in Hefei, Anhui province. Zhang Hongwen, Vice governor of Anhui Provincial People's Government, delivered a welcome speech, and Yan Jiangying, member of the Party group and deputy director of the State Medical Products Administration, attended the opening ceremony and delivered a speech.

Yan Jiangying pointed out that the deep integration of the pharmaceutical industry, drug supervision and information technology is an inevitable development, and it is also a breakthrough point for future supervision and reform. In recent years, the Internet has given birth to big data, which has promoted continuous breakthroughs in artificial intelligence and helped the world enter a new era of digitalization, networking and intelligent integrated development. In the pharmaceutical industry, we can feel the great changes brought by new technologies: evidence-based decision-making based on data has become the basic criteria for drug research and development, the transformation of pharmaceutical companies to digital and intelligent has become the development direction, e-commerce and modern logistics have become an important way to improve product accessibility. In the future, in the whole process of research and development, production, circulation and use of drugs, medical devices and cosmetics, the wave of big data is surging everywhere, and the power of information technology to reshape the industry is highlighted everywhere.

Yan Jiangying stressed that the smart regulation of drugs has reached a new level, and the next step is to adhere to "one center", that is, to take the people as the center. Consciously implement the concept of "people first, life first", give full play to the unique advantages of big data "pooling people's wisdom, sharing people's worries, and solving people's difficulties", continue to optimize "Internet + government services", accelerate the realization of "One network to do", and build a "concentric bridge" of information for the convenience of the people; We must adhere to the "two main lines", that is, to ensure security and maintain the bottom line and promote development and pursue a high line. Build information means into the "clairvoyant eyes and wind ears" of regulatory departments, strengthen data aggregation, governance, analysis, and utilization, and promote digital management of the whole life cycle. At the same time, the use of information service industry development, better guarantee drug safety, maintain market order, accelerate product research and development; We should adhere to the "three commonalities", that is, joint construction, joint governance and shared benefits. Co-construction is for co-governance, co-governance cannot be separated from sharing, smart supervision is a systematic project, requires all parties to work together, form a joint force, and jointly build a drug safety firewall.

With the theme of "Data service Development, Innovation and wisdom for the future", the conference aims to promote the high-quality development of drugs, coordinate development and safety, coordinate industrial needs and regulatory needs, continue to consolidate and expand the achievements of epidemic prevention and control and economic and social development, better serve the "six stability" and "six protection", and better lead the modernization of drug regulation with information technology.

At the meeting, the "Anhui Collaborative Innovation Platform of China Food and Drug Supervision Data Center" was officially launched, the typical case of drug smart supervision in 2021 was officially released, and the "UDI Service public welfare Platform" was officially launched. The whole system and the whole industry have formed a consensus on accelerating smart supervision and industry transformation and upgrading.

At the main forum of the conference, The responsible comrades of the relevant departments of the Ministry of Industry and Information Technology, the General Administration of Market Supervision and the State Food and Drug Administration respectively made the "status quo and development focus of intelligent manufacturing in the pharmaceutical industry", "Practice and reflection on the construction of intelligent supervision based on credit data" and "step-by-step promotion of the drug traceability system. Improving the level of drug safety "Digital smart Review helps Cosmetics innovation and development" "Digital Technology promotes the modernization of drug research and development and supervision" "Digital medical device Review Reform" "Off-site Remote Inspection of drugs and digital intelligent Development" theme report. Local bureaus such as Beijing Municipal Food and Drug Administration, Zhejiang Provincial Food and Drug Administration and Anhui Provincial Food and Drug Administration shared typical cases of smart supervision. Typical cases of relevant information technology enterprises were also shared.

In order to increase the exchange of ideas of diversity, cross-border and integration, the provincial bureau responsible comrades were also organized during the meeting to conduct in-depth discussions on the information work of drug supervision. In addition to the main venue, the conference also added four theme chapters, "Building a new pattern of social co-governance with credit", "UDI Innovation Application", "Enterprise digital Factory and Digital Transformation" and "Digital innovation in the cosmetics industry". The main comrades in charge or in charge of the drug administration of 26 provinces (autonomous regions and municipalities), including Beijing, Tianjin, Inner Mongolia, Liaoning, Jilin, Zhejiang, Anhui, Jiangxi, Hainan, Chongqing, Sichuan, Xizang, Shaanxi, Gansu, Qinghai and Xinjiang, participated in the conference and exchanged experience and shared gains on the smart supervision work.